bioRxiv Science⌕ Search

bioRxiv · 10.64898/2026.01.07.698100

Designing epitope-based vaccines against Nipah virus Glyco and Fusion proteins using integrated immunoinformatics and structural modeling techniques

Abstract

Nipah virus (NiV) is a re-emerging zoonotic virus belonging to the Paramyxoviridae family that results in significant neurological damage and raises fatality rates. NiV is classified as a stage III pathogen with a high likelihood of transmission to humans, causing outbreaks intermittently and without any predictable pattern. In Bangladesh, outbreaks of NiV have happened every year since 2001. Even though the disease is severe, no antiviral medications exist for NiV infections. As a consequence, developing a vaccine is crucial. The present research aims to predict an effective epitope-based vaccine by applying immunoinformatic techniques against the fusion and glycoprotein of the Nipah virus. Fusion and glycoproteins were obtained from the UniProt protein database and screened for the T and B cell epitopes using the IEDB and ABCpred servers. Moreover, the constructed 3D structure of the NiV vaccine was occupied with Toll-like receptor 4 for molecular docking and dynamic (MD) simulation studies. Finally, the vaccine design was validated for expression in the PET28a (+) vector of Escherichia coli, and immunological simulations were also conducted. After determination of the allergenicity, antigenicity, and toxicity, the non-allergenic, nontoxic, antigenic, and immunogenic epitopes were used to construct the vaccine with adjuvants and an appropriate linker, including AAY, GPGPG, and KK. The constructed NiV vaccine was confirmed based on its physicochemical properties and docking scores for further analysis. The MD simulations indicated a stabilized structure and increased duration of epitope visibility, indicating strong immune responses. Furthermore, codon optimization and in silico cloning were used to verify bacterial expression of the developed NiV vaccine in E. coli. The results showed that NiV can increase immune responses against the Nipah virus. Furthermore, in vitro and in vivo research and clinical studies are recommended to establish the findings of this study.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Biswas, S., Kamaruzzaman, M., Alam, M. B. S., Iqbal, M. J., Jamila, M., Zahan, T.. 2026-01-08. Designing epitope-based vaccines against Nipah virus Glyco and Fusion proteins using integrated immunoinformatics and structural modeling techniques. https://doi.org/10.64898/2026.01.07.698100

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Ksp37 is a rapidly mobilized NK cell secretory protein that engages FGF2

A key feature of natural killer (NK) cells is their preloaded arsenal of effector molecules, allowing them to rapidly respond upon activation. In this study, we characterized a previously unexplored secretory protein, termed killer-specific secretory protein of 37 kDa (Ksp37), which is highly abundant in differentiated CD56dim NK cells. Ksp37 is rapidly secreted in a dose-dependent and JAK-1 dependent manner upon low levels of cytokine stimulation, making it a sensitive readout for NK cell activation. Following secretion, intracellular levels were rapidly replenished, preserving responsiveness to subsequent cytokine stimulation. We found that Ksp37 is stored in polarized intracellular compartments distinct from those containing canonical cytotoxic effector molecules, including granzyme B and perforin, which require stronger stimulation for release. Lastly, we identified Ksp37 as a novel binding partner of fibroblast growth factor 2 (FGF2). This opens new avenues of exploration for the role of NK cells in remodeling their extracellular environment by modulating the FGF2-FGFR1 axis, which plays a key role in tumor growth, angiogenesis and tissue repair.

immunology↗

ACE-engineered human iPSC-derived neutrophils enhance host defense against multidrug-resistant bacterial infections

Severe neutropenia predisposes patients to life-threatening infections, while donor-dependent granulocyte transfusions are limited by availability and variable cell quality. Here, we engineered human induced pluripotent stem cells (iPSCs) to constitutively or inducibly express angiotensin-converting enzyme (ACE) and differentiated them into functional ACE-engineered neutrophils (ACE-iNeu). ACE expression enhanced granulocytic maturation, reactive oxygen species generation, inflammatory cytokine production, and antimicrobial signaling. ACE-iNeu exhibited enhanced bactericidal activity against methicillin-resistant Staphylococcus aureus and multidrug-resistant Pseudomonas aeruginosa. Following adoptive transfer into neutropenic mice, ACE-iNeu significantly reduced circulating and tissue bacterial burdens. Integrated metabolomic and transcriptomic analyses revealed ACE-associated alterations in adenine nucleotide abundance and developmental and inflammatory pathways. Together, these findings establish ACE engineering as a strategy to enhance the production and antimicrobial function of human iPSC-derived neutrophils and support further preclinical development of engineered granulocyte therapies for severe drug-resistant infections.

immunology↗

Tetravalent dengue mRNA vaccination orchestrates balanced four-serotype immunity with durable memory and protection in mice.

An effective dengue vaccine must establish durable immunity across four dengue virus (DENV) serotypes, evade antibody-dependent enhancement (ADE), and overcome immune imprinting from prior exposure. Here, we developed TetprM-E mRNA-LNP, a tetravalent vaccine comprising LNP-formulated nucleoside-modified mRNAs encoding DENV1-4 precursor membrane-envelope (prM-E) antigens, and evaluated its immunogenicity, durability, protection and breath across serotype-specific immune backgrounds. Three immunization strategies elicited neutralizing titers greater than 1:1500 against each serotype. Passive transfer of immune sera conferred 100% survival and reduced viremia after lethal DENV2 challenge in immunocompromised mice. Vaccination induced DENV envelope (env)-specific CD8+T cells and CD4-dependent germinal-center responses. DENV env-binding antibodies persisted for 34 weeks alongside DENV env-specific memory B cells. Vaccine-elicited sera showed no measurable in vitro ADE. Although monovalent priming initially biased antibody responses, TetprM-E mRNA-LNP vaccination broadened neutralization across DENV1-4 regardless of priming serotype. Together, TetprM-E mRNA-LNP elicits broad, durable, and protective immunity despite serologic constraints from pre-existing immunity.

immunology↗